ABT-199: Taking Dead Aim at BCL-2

被引：74

作者：

Davids, Matthew S. ^{[1
]}

Letai, Anthony ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

来源：

CANCER CELL | 2013年 / 23卷 / 02期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; FAMILY; ABT-737;

D O I：

10.1016/j.ccr.2013.01.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer therapies.

引用

页码：139 / 141

页数：3

共 50 条

[1] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang
Chaitanya Iragavarapu
John Savooji
Yongping Song
Delong Liu
Journal of Hematology & Oncology, 8
[2] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, Shundong
Iragavarapu, Chaitanya
Savooji, John
Song, Yongping
Liu, Delong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
[3] Quantitative assessment of BCL-2: BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199)
Jin, Sha
Tapang, Paul
Osterling, Donald J.
Gao, Wenqing
Albert, Daniel H.
Souers, Andrew J.
Leverson, Joel D.
Phillips, Darren C.
Chen, Jun
CANCER RESEARCH, 2015, 75
[4] Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma
Matulis, Shannon
Nooka, Ajay K.
Von Hollen, Hayley
Kaufman, Jonathan L.
Lonial, Sagar
Boise, Lawrence H.
BLOOD, 2014, 124 (21)
[5] ABT-199, a Selective Small Molecule Inhibitor of Bcl-2, Exhibits Efficacy in Bcl-2 Dependent Malignancies While Sparing Platelets
Leverson, J.
Souers, A.
Boghaert, E.
Phillips, D.
Park, C.
Wendt, M.
Fairbrother, W.
Humerickhouse, R.
Roberts, A.
Elmore, S.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 23 - 23
[6] ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J Souers
Joel D Leverson
Erwin R Boghaert
Scott L Ackler
Nathaniel D Catron
Jun Chen
Brian D Dayton
Hong Ding
Sari H Enschede
Wayne J Fairbrother
David C S Huang
Sarah G Hymowitz
Sha Jin
Seong Lin Khaw
Peter J Kovar
Lloyd T Lam
Jackie Lee
Heather L Maecker
Kennan C Marsh
Kylie D Mason
Michael J Mitten
Paul M Nimmer
Anatol Oleksijew
Chang H Park
Cheol-Min Park
Darren C Phillips
Andrew W Roberts
Deepak Sampath
John F Seymour
Morey L Smith
Gerard M Sullivan
Stephen K Tahir
Chris Tse
Michael D Wendt
Yu Xiao
John C Xue
Haichao Zhang
Rod A Humerickhouse
Saul H Rosenberg
Steven W Elmore
Nature Medicine, 2013, 19 : 202 - 208
[7] The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199
Choo, Edna F.
Boggs, Jason
Zhu, Chunqiang
Lubach, Joseph W.
Catron, Nathaniel D.
Jenkins, Gary
Souers, Andrew J.
Voorman, Richard
DRUG METABOLISM AND DISPOSITION, 2014, 42 (02) : 207 - 212
[8] Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer
Jing Deng
Anthony Letai
Breast Cancer Research, 15
[9] ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, Andrew J.
Leverson, Joel D.
Boghaert, Erwin R.
Ackler, Scott L.
Catron, Nathaniel D.
Chen, Jun
Dayton, Brian D.
Ding, Hong
Enschede, Sari H.
Fairbrother, Wayne J.
Huang, David C. S.
Hymowitz, Sarah G.
Jin, Sha
Khaw, Seong Lin
Kovar, Peter J.
Lam, Lloyd T.
Lee, Jackie
Maecker, Heather L.
Marsh, Kennan C.
Mason, Kylie D.
Mitten, Michael J.
Nimmer, Paul M.
Oleksijew, Anatol
Park, Chang H.
Park, Cheol-Min
Phillips, Darren C.
Roberts, Andrew W.
Sampath, Deepak
Seymour, John F.
Smith, Morey L.
Sullivan, Gerard M.
Tahir, Stephen K.
Tse, Chris
Wendt, Michael D.
Xiao, Yu
Xue, John C.
Zhang, Haichao
Humerickhouse, Rod A.
Rosenberg, Saul H.
Elmore, Steven W.
NATURE MEDICINE, 2013, 19 (02) : 202 - 208
[10] Remarkable early clinical activity with the Bcl-2 selective inhibitor ABT-199: Proving the concept.
Humerickhouse, Rod
CANCER RESEARCH, 2013, 73 (08)

← 1 2 3 4 5 →